REG - Proteome Sciences - Director/PDMR Shareholding

Proteome SciencesAnnouncement

22/03/2018 13:20

RNS Number : 6389I
Proteome Sciences PLC
22 March 2018
 

Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company announces that on 21 March 2018 Roger McDowell, a Non-Executive Director of the Company, sold 500,000 ordinary shares of 1 pence each ("Ordinary Shares") at a price of 3 pence per Ordinary Share and bought, into his SIPP, 500,000 Ordinary Shares at a price of 3.006 pence per Ordinary Share (the "Transfer").
Following the Transfer, Mr McDowell's beneficial interest in the Company remains at 2,500,000 Ordinary Shares representing approximately 0.91% of the issued share capital of the Company.




For further information:
Proteome Sciences plc




Jeremy Haigh, Chief Executive Officer                       Tel: +44 (0)20 7043 2116




Ian Pike, Chief Scientific Officer








Stefan Fuhrman, Finance Director




 
finnCap Limited (Nominated Adviser/Broker)


 
        




Geoff Nash/James Thompson


        Tel: +44 (0)20 7220 0500




Tony Quirke (broking)








               




About Proteome Sciences plc. (www.proteomics.com):
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
 Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.




1.               


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Roger McDowell




2.               


Reason for the Notification




a)


Position/status


Non-Executive Director




b)


Initial notification/Amendment


Initial notification




3.    


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Proteome Sciences plc




b)


LEI


213800Q62ICXANKU2986




4.    


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the Financial instrument, type of instrument


Ordinary Shares of 1p each




Identification code


GB0003104196




b)


Nature of the transaction


Purchase and sale of shares




c)


Price(s) and volume(s)


500,000 Ordinary Shares bought at 3.006p per Ordinary Share
500,000 Ordinary Shares sold at 3.000p per Ordinary Share
 




d)


Aggregated information:
·      Aggregated volume
·      Price


500,000 Ordinary Shares bought at 3.006p per Ordinary Share
500,000 Ordinary Shares sold at 3.000p per Ordinary Share
 




e)


Date of the transaction


21 March 2018




f)


Place of the transaction


London Stock Exchange, AIM Market (XLON)




 



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHSEMFDEFASEFD